# A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

> **NCT00603941** · PHASE1,PHASE2 · TERMINATED · sponsor: **Daiichi Sankyo** · enrollment: 19 (actual)

## Conditions studied

- Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** CS-7017
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00603941
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated dose could not be established
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00603941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00603941, "A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00603941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*